OncoZenge (ONCOZ) investor relations material

Market need and patient impact

• Oral mucositis affects over one-third of cancer patients in Europe, causing severe pain and impacting quality of life.

• Standard treatments like lidocaine, mouthwashes, and opioids often fail to provide sufficient relief.

• Patients experience significant weight loss, risk of opioid dependence, and increased healthcare costs due to complications.

Product innovation and clinical progress

• Developed BupiZenge, a dissolving lozenge using bupivacaine, offering localized pain relief for oral mucositis.

• Phase III clinical trial is underway, with eight hospitals in Europe actively recruiting by end of September.

• Clinical trial application approved in May, first patient recruited in July, aiming for clinical study report early next year.

Commercial and partnership strategy

• Chose a partner-based commercial strategy, avoiding building own sales force for a single product.

• Signed European distribution partnership with Molteni, a specialist in pain and addiction, covering over 40 countries.

• Active discussions with pharma companies globally, with Asia-Pacific seen as the next likely region for partnership.